Skip to main content
. Author manuscript; available in PMC: 2022 Nov 1.
Published in final edited form as: Clin Gastroenterol Hepatol. 2020 Oct 16;19(11):2407–2416.e8. doi: 10.1016/j.cgh.2020.10.026

Table 2.

Provider Attitudes and Practices for Alcohol Screening, Treatment and Education in Patients with Liver Disease (n = 420)

Provider question Data
How often do you ask about alcohol use to a new patient with liver disease?
 Never/rarely 0
 Sometimes 3 (0.7%)
 Usually 21 (5.0%)
 Always 396 (94.3%)
How often you ask about frequency of alcohol use?
 Never/rarely 1 (0.2%)
 Sometimes 3 (0.7%)
 Usually 32 (7.6%)
 Always 384 (92.4%)
How often do you ask about quantity of alcohol use?
 Never/rarely 2 (0.5%)
 Sometimes 15 (3.6%)
 Usually 62 (14.8%)
 Always 341 (81.2%)
How often do you use a brief screening tool in a new patient with liver disease?*
 Never/rarely 198 (47.1%)
 Sometimes 129 (30.7%)
 Usually 56 (14.8%)
 Always 37 (8.8%)
How often do you monitor alcohol use with biomarkers?
 Never/rarely 121 (28.8%)
 Sometimes 131 (31.2%)
 Usually 113 (26.9%)
 Always 55 (13.1%)
How often do you personally prescribe AUD pharmacotherapy?
 Never/rarely 288 (70.6%)
 Sometimes 93 (22.8%)
 Usually 16 (3.9%)
 Always 11 (2.7%)
How comfortable are you prescribing AUD pharmacotherapy?+
 Not comfortable 227 (55.6%)
 Somewhat comfortable 115 (28.2%)
 Comfortable 42 (10.3%)
 Very comfortable 24 (5.9%)
What proportion of your AUD patients are taking any AUD pharmacotherapy? (on- or off-label)+
 0–25 353 (86.5%)
 26–50 42 (10.3%)
 51–75 9 (2.2%)
 76–100 4 (1.0%)
Provider education in addiction medicine+
 None 105 (25.7%)
 <1 month 209 (51.2%)
 1–3 month 39 (9.6%)
 >3 month 20 (4.9%)
 Other/unknown 35 (8.6%)

AUD, alcohol use disorder

*

Such as the Alcohol Use Disorders Identification Test—Concise, the Single Alcohol Screening Question, or the CAGE questionnaire

+

n = 408